Condition: HIV Prevention · Sponsor: University of Witwatersrand, South Africa
This is a single-arm, open-label, effectiveness study designed to evaluate the use of Tenofovir, Lamivudine, and Dolutegravir in people with newly diagnosed HIV-1 infection initiating first-line Antiretroviral Therapy with Cabotegravir-Long-acting Pre-Exposure Prophylaxis exposure in the preceding 12 months. Participants will be followed up for a period of 12 months from enrolment.
This description comes directly from the study's public registry record.
BUKANI X DYARIWE · 0110844961 · bdyariwe@ezintsha.org
SIMISO M SOKHELA, MBChB · 0110844933 · ssokhela@ezintsha.org
Always discuss trial participation with your own doctor first.
| Ezintsha, a division of Wits Health Consortium | Johannesburg, Gauteng, South Africa | Recruiting |
| Africa Health Research Institute (AHRI) | Durban, KwaZulu-Natal, South Africa | Recruiting |
| Desmond Tutu Health Foundation | Cape Town, Western Cape, South Africa | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06485154